Frontiers in Virology, published by FRONTIERS MEDIA SA, is an innovative open-access journal dedicated to advancing the understanding of viral biology, pathogenesis, surveillance, and control strategies. With the rapid evolution of viral threats, this journal serves as a critical platform for researchers, professionals, and students to disseminate and access high-quality research, reviews, and perspectives in virology. The journal places a strong emphasis on interdisciplinary approaches, promoting collaborative efforts that drive breakthroughs in the field. While the specific impact factor and H-index details are currently unavailable, Frontiers in Virology is committed to rigorous peer review and integrity in scientific publishing. Authors and readers will benefit from the extensive reach provided by open access, making groundbreaking insights available to a global audience, thus contributing significantly to the ongoing dialogue in virology and public health.

Advances in Virology, an esteemed journal published by HINDAWI LTD, serves as a pivotal platform for cutting-edge research in the field of virology and infectious diseases. With its ISSN 1687-8639 and E-ISSN 1687-8647, the journal has been a significant contributor to the scientific community since its initiation as an Open Access resource in 2009, allowing researchers from around the globe to access groundbreaking findings without barriers. Operating out of the United States and recognized for its commitment to high-quality research, the journal's relevance is underscored by its ranking in the Q3 category for Infectious Diseases and Q4 for Virology as of 2023. The time frame of publications spans from 2009 to 2024, reflecting a continuous commitment to exploring the evolving landscape of virology. This journal not only promotes the dissemination of novel insights and methodologies but also fosters collaboration and innovation within the scientific community, making it an invaluable resource for researchers, professionals, and students alike.

VIRUS RESEARCH is a leading journal dedicated to the field of virology, published by Elsevier, and has been a cornerstone for researchers, professionals, and students since its inception in 1984. With an impressive impact factor, the journal is highly regarded, holding a Q2 category ranking in both Cancer Research and Infectious Diseases, as well as in Virology for 2023. Based in the Netherlands, it publishes high-quality, peer-reviewed articles that explore the intricate relationships between viruses and their hosts, novel therapeutic strategies, and advancements in virus biology. Researchers will find that it ranks 49th in Medicine - Infectious Diseases and 19th in Immunology and Microbiology - Virology according to Scopus, signifying its significant contribution and relevance in the academic world. VIRUS RESEARCH facilitates a platform for sharing groundbreaking discoveries, forming a vital part of the global scientific community, making it an essential read for those involved in the study of viral pathogens and their implications in medicine and biochemistry.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Current HIV Research is a pivotal journal dedicated to the latest advancements in the field of HIV research, published by Bentham Science Publishers Ltd. With a commitment to disseminating high-quality research, this journal serves as a critical resource for researchers, healthcare professionals, and students interested in infectious diseases and virology. The journal has an ISSN of 1570-162X and an E-ISSN of 1873-4251, reflecting its commitment to contemporary digital scholarship. Given its publication history spanning from 2003 to 2024, the journal has continually provided insights and peer-reviewed articles that foster knowledge and innovation in HIV research. Although it currently holds a Q3 ranking in Infectious Diseases and a Q4 ranking in Virology, these rankings underscore its importance as an emerging platform for critical research dialogue. Despite not being an Open Access journal, 'Current HIV Research' ensures that cutting-edge studies reach relevant practitioners and contribute to ongoing discourse in the medical community. By fostering an informed approach to HIV and its implications, this journal is an invaluable asset to those committed to advancing their expertise in this crucial area of health science.

Hepatitis Monthly, published by BRIEFLAND in the Netherlands, is a pivotal journal in the fields of hepatology and infectious diseases. Established in 2007, it continues to make significant contributions to the understanding and management of hepatitis and related viral infections with a publication timeline extending through to 2024. Aiming to disseminate high-quality research, the journal serves as a forum for groundbreaking studies and innovations essential for healthcare professionals, researchers, and students alike. While it currently holds Q4 rankings in both hepatology and infectious disease categories, its ongoing commitment to addressing pressing health issues makes it an important resource in the academic community. Although it operates under a traditional access model, Hepatitis Monthly not only publishes original research articles, reviews, and case studies but also encourages the exchange of knowledge that helps shape future research directions and clinical practices. As it continues to explore the complexities surrounding viral hepatitis, this journal invites researchers to contribute to its mission of advancing scientific understanding and improving patient care.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.

Future Virology, published by Future Medicine Ltd, is an essential journal dedicated to advancing the understanding of virology in the contemporary scientific landscape. With an ISSN of 1746-0794 and an E-ISSN of 1746-0808, this journal serves as a platform for researchers and practitioners in the field to publish high-quality, peer-reviewed articles that explore novel discoveries, innovative therapeutic strategies, and the implications of viral research on global health. Operating from the United Kingdom and maintaining a commitment to rigorous scientific inquiry, Future Virology is categorized in the Q4 Quartile for Virology according to the latest Scopus rankings, with a position of Rank #48/80 and a percentile of 40th in the Virology category. Although it currently does not offer open access, the journal strives to disseminate critical insights that benefit a wide range of professionals, researchers, and students engaged in virology and related fields. By bridging the gap between basic research and practical applications, Future Virology plays a crucial role in fostering innovation and collaboration in the ever-evolving virology landscape.

The Journal of Clinical Virology Plus, published by Elsevier, is an essential resource for researchers and professionals in the fields of virology and infectious diseases. Launched in 2021, this journal aims to bridge the gap between clinical research and application, fostering a deeper understanding of viral pathogenesis, diagnostics, and therapeutic strategies. With an ISSN of 2667-0380, this open-access journal brings cutting-edge findings to the global scientific community, facilitating the rapid dissemination of knowledge critical for advancing public health. Positioned in the Q3 category for both Infectious Diseases and Virology in 2023, its ranking reflects its growing influence and relevance in the academic landscape. The journal strives to support innovative research, collaborative studies, and comprehensive reviews that address contemporary challenges in clinical virology. As it converges through the years from 2021 to 2024, Journal of Clinical Virology Plus aims to be a central hub for vital discussions and breakthroughs in this dynamic field.

ANTIVIRAL RESEARCH, published by Elsevier, stands at the forefront of the study of antiviral agents and therapy, with a dedicated focus on advancing the understanding of viral infections and their mechanisms. The journal is recognized within the top tier of academic publications, belonging to the prestigious Q1 category in both Pharmacology and Virology as of 2023, ranking 12th out of 313 in Pharmacology and 11th out of 80 in Virology according to Scopus metrics, reflecting its significant impact in the field. With a long-standing history since its inception in 1959, it continues to serve as an essential platform for researchers and health professionals alike, sharing critical findings that drive innovation in antiviral therapeutics. Although it does not currently offer open access options, the journal’s rigorous peer-review process ensures that every published article meets high academic standards, providing invaluable insights for those dedicated to enhancing public health through virology research.